Statera BioPharma(STAB)
$0.00+0.00 (+100.00%)
STAB
Statera BioPharma financials statements
$0.00
At close:+0.00 (+100.00%)
Statera BioPharma (STAB) Ratios
191 Followers
Statera BioPharma Ratios
STAB's free cash flow for Q3 2022 was $-801.52K. For the 2022 fiscal year, STAB's free cash flow was decreased by $-2.00 and operating cash flow was $-801.52K. See a summary of the company’s cash flow.
| Ratios | Dec 21 | Dec 20 | Dec 19 | Dec 18 | Dec 17 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.37 | 0.20 | 0.00 | 4.91 | 4.33 |
| Quick Ratio | 0.37 | 0.20 | 0.28 | 4.91 | 4.33 |
| Cash Ratio | 0.16 | 0.13 | 0.00 | 3.97 | 1.91 |
| Solvency Ratio | -7.68 | -2.82 | -2.19 | -3.90 | -4.36 |
| Operating Cash Flow Ratio | -2.51 | -1.10 | -0.16 | -5.06 | -2.99 |
| Short-Term Operating Cash Flow Coverage | -6.16 | -2.67 | -0.13 | 0.00 | 0.00 |
| Net Current Asset Value | $ -18.52M | $ -3.77M | $ -1.52M | $ 3.56M | $ 7.36M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.77 | 1.93 | 1093.64 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | -10.37 | -0.55 | -0.43 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 1.11 | -1.21 | -0.75 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 1.17 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | -13.50 | -0.28 | -0.00 | -3.12 | 4.38 |
| Debt Service Coverage Ratio | -53.15 | -3.99 | -1.66 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | -9.29 | -22.65 | 0.00 | 0.00 |
| Debt to Market Cap | 0.19 | 0.01 | 0.01 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.46 | 0.12 | 0.08 | 0.00 | 0.00 |
| Net Debt to EBITDA | -0.08 | -0.13 | -0.58 | 0.75 | 0.76 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 171.20% | 109.35% | 103.85% | 100.00% | 100.00% |
| EBT Per EBIT | 103.59% | 115.16% | 114.56% | 75.25% | 173.30% |
| Return on Assets (ROA) | -823.86% | -1277.14% | -202924.55% | -79.66% | -100.80% |
| Return on Equity (ROE) | 11122.70% | 361.75% | 79.53% | 248.77% | -441.26% |
| Return on Capital Employed (ROCE) | -990.93% | 292.90% | 185.28% | -132.50% | -75.52% |
| Return on Invested Capital (ROIC) | -666.54% | 635.55% | -880.08% | -132.50% | -75.12% |
| Return on Tangible Assets | -1689.72% | -1277.14% | -202924.55% | -79.66% | -100.80% |
| Earnings Yield | -215.98% | -10.29% | -2.61% | -6.38% | -17.31% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.12 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2963.69 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 2963.69 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.80 | -0.20 | -0.01 | -0.41 | -0.59 |
| Free Cash Flow Per Share | -0.81 | -0.20 | -0.01 | -0.41 | -0.59 |
| Dividend Paid and CapEx Coverage Ratio | -154.09 | -527.36 | 0.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | -154.09 | -527.36 | 0.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -1.73 | -2.54 | -0.13 | 0.00 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -35.14% | -3.96% | -0.19% | -8.15% | -11.79% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.46 | -9.72 | -38.38 | -15.67 | -5.78 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -51.50 | -35.15 | -30.53 | -38.97 | 25.49 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.85 | -25.24 | -534.62 | -12.26 | -8.48 |
| Price-to-Operating Cash Flow Ratio | -2.86 | -25.29 | -534.62 | -12.26 | -8.48 |
| Price-to-Earnings Growth (PEG) Ratio | -0.00 | -0.03 | 0.65 | 0.25 | -0.02 |
| Enterprise Value Multiple | -0.56 | -11.85 | -42.23 | -11.03 | -9.26 |
| Enterprise Value | 95.17M | 129.92M | 130.31M | 52.96M | 51.84M |
| EV to EBITDA | -0.56 | -11.85 | -42.23 | -11.03 | -9.26 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -3.35 | -25.51 | -542.12 | -11.48 | -7.84 |
| EV to Operating Cash Flow | -3.38 | -25.56 | -542.12 | -11.48 | -7.84 |
| Tangible Book Value Per Share | -0.35 | -0.14 | -0.06 | 0.32 | 0.66 |
| Shareholders’ Equity Per Share | -0.04 | -0.14 | -0.16 | -0.13 | 0.20 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.71 | -0.09 | -0.04 | 0.00 | 0.01 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -4.97 | -0.52 | -0.13 | -0.32 | -0.87 |
| Tax Burden | 1.71 | 1.09 | 1.04 | 1.00 | 1.00 |
| Interest Burden | 0.60 | 1.10 | 1.04 | 0.75 | 1.73 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.28 | 1.20 | 0.07 | 1.24 | 0.67 |
Currency in USD
